Moderna, Inc., valued at $13 billion, focuses on developing mRNA-based therapies for various conditions. Analysts expect a 10.8% decrease in earnings per share for Q2 2025 compared to the same quarter last year. The company’s stock has plummeted 72.6% over the past year, falling from its all-time high due to decreased demand for COVID-19 vaccines.

Despite mixed Q1 2025 results, Moderna’s stock fell 5.3% as revenue decreased by 35.3% year-over-year. Analysts have mixed opinions on the stock, with a consensus “Hold” rating and trading below the mean price target of $42.86. The company is set to announce its Q2 results on August 7.

Read more at Yahoo Finance: What to Expect From Moderna’s Next Quarterly Earnings Report